Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist

C-reactive protein (CRP) is made in liver and its Serum concentration increases in inflammation. Measurement of serum CRP is recommended for use as an indicator of inflammation and predictor of atherosclerosis. Cholesterol-lowering drugs statins also lower CRP. To evaluate statin-mediated CRP reduction and to reassess clinical usefulness of CRP, we investigated regulation of CRP gene expression. Here. we show that mediated CRP reduction and to reassess clinical usefulness of CRP, we investigated regulation of CRP gene expression. Here, we show that pravastatin and simvastatin prevent the induction of CRP expression in human hepatoma Hep3B cells exposed to proinflammatory cytokines IL-6 and IL-1 beta. The nitric oxide (NO) donor, sodium nitroprusside, also prevented the induction of CRP expression while the CRP inducers IL-6 and IL-1 beta were present with the cells. The effect of NO on CRP expression was at the level of transcription. These findings Suggest that the decrease in CRP level in vivo after statin-treatment does not necessarily reflect absence of inflammation. and that NO-releasing drugs have the potential to reduce serum CRP levels. Thus, the measurement of serum CRP levels alone in individuals on statin/NO-therapy is not as useful as was imagined. (C) 2005 Elsevier Ltd. All rights reserved.